For example, liposome AOSs reverse multi-drug resistance in vivo and in vitro by inhibiting the expression of P-GP, MRP1, MRP2 and Bcl-2/Bcl-XL, which may enhance the sensitivity of CRC to chemotherapy by decreasing the activity level of the MDR1 promoter [15,16]. Here, BCL2 is linked to colorectal carcinoma.